According to our recent payer coverage analysis for hereditary angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for HAE treatments shows that under the pharmacy benefit, about 57% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: Health plans don’t differentiate coverage among provider-administered products, and access to HAE products is not limited at the brand level. However, increased competition is expected as more prophylactic therapies enter the market.